Tayyebeh M. Nazeran

No ORCID on file · 19 papers in corpus
lab-animal 2026
Clinical and experimental reproductive medicine ·doi:10.5653/cerm.2025.09110

OBJECTIVE: Postoperative adhesions and inflammation remain major challenges following endometriosis surgery. Human amniotic membrane gel (HAG) has emerged as a potential therapeutic strategy with both anti-adhesive and anti-inflammatory pro…

observational 2023
The journal of pathology. Clinical research ·doi:10.1002/cjp2.317

The clinical phenotype of somatic mutations in endometriosis is unknown. The objective was to determine whether somatic KRAS mutations were associated with greater disease burden in endometriosis (i.e. more severe subtypes and higher stage)…

observational 2022
Fertility and sterility ·doi:10.1016/j.fertnstert.2022.05.030

OBJECTIVE: To investigate the heterogeneity of somatic cancer-driver mutations within patients and across endometriosis types. DESIGN: A single-center cohort, retrospective study. SETTING: Tertiary specialist-care center at a university h…

2021
·doi:10.1101/2021.04.12.21255355

Abstract Endometriosis symptoms are heterogeneous with controversy on whether it constitutes a single disease or multiple distinct types. Our previous work found recurrent somatic cancer-driver alterations in endometriosis; however, these h…

observational 2021
·doi:10.1101/2021.09.16.21262993

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumor suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory repo…

observational 2021
The Journal of Pathology ·doi:10.1002/path.5849

ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory reports on i…

observational 2020
British journal of cancer ·doi:10.1038/s41416-020-0900-0

BACKGROUND: PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarke…

2020
·doi:10.1055/s-0040-1718045

Endometriosis has yielded controversy on whether it constitutes a single disease or distinct types. Current classification systems poorly correlate with the severity of symptoms and do not provide prognostic tools that can guide management …

lab-animal 2019
·doi:10.1158/1557-3265.ovcasymp18-gmm-020

Abstract Both clear cell ovarian carcinoma (CCOC) and endometrioid ovarian carcinoma (ENOC) are associated with ovarian endometriotic cysts, which is believed to be their precursor lesion. However, genomic evidence is lacking which could ex…

other 2019
Gynecologic Oncology ·doi:10.1016/j.ygyno.2019.07.012

OBJECTIVE: Endometrioid ovarian carcinomas (EOCs) comprise 5-10% of all ovarian cancers and commonly co-occur with synchronous endometrioid endometrial cancer (EEC). We sought to examine the molecular characteristics of pure EOCs in patient…

observational 2019
The Journal of Pathology ·doi:10.1002/path.5314

The advent of next generation sequencing has vastly improved the resolution of mutation detection, thereby both increasing the resolution of the analysis of cancer tissues and shining light on the existence of somatic driver mutations in no…

observational 2019
·doi:10.1101/561050

Abstract The presence of somatic driver mutations in endometriosis has previously been believed to represent early events in transformation, however our group and others have described such mutations in roughly one-third of cases of deep in…

2018
·doi:10.1158/1557-3265.ovca17-b22

Abstract Endometrioid ovarian cancer (ENOC) and clear cell ovarian cancer (CCOC) share a common precursor lesion, endometriosis (ectopic growth of uterine lining), hence the designation endometriosis-associated ovarian cancer (EAOC). Women …

lab-animal 2018
·doi:10.1158/1557-3265.ovca17-b39

Abstract Both clear cell ovarian carcinoma (CCOC) and endometrioid ovarian carcinoma (ENOC) are associated with ovarian endometriotic cysts, which is believed to be the precursor lesion of these cancers. Women with endometriotic cysts have …

observational 2018
Human Reproduction ·doi:10.1093/humrep/dey332

STUDY QUESTION: Does incisional endometriosis (IE) harbor somatic cancer-driver mutations? SUMMARY ANSWER: We found that approximately one-quarter of IE cases harbor somatic-cancer mutations, which commonly affect components of the MAPK/RA…

2017
·doi:10.1158/1557-3265.ovcasymp16-ap09

Abstract BACKGROUND: Endometriosis affects ~10% of reproductive–aged women and is characterized by extra–uterine biphasic growth of uterine endometrial epithelium and stroma. Endometriosis is widely considered to be a hormonally–dependent i…

2017
·doi:10.1158/1557-3265.ovcasymp16-dpoc-014

Abstract PURPOSE: Women with endometriosis, a painful condition caused by displaced endometrial tissue, have a 3-fold increased risk of developing endometrioid ovarian cancer (ENOC) and clear cell ovarian cancer (CCOC). How two distinct can…

other 2017
New England Journal of Medicine ·doi:10.1056/nejmoa1614814

BACKGROUND: Endometriosis, defined as the presence of ectopic endometrial stroma and epithelium, affects approximately 10% of reproductive-age women and can cause pelvic pain and infertility. Endometriotic lesions are considered to be benig…

other 2017
Gynecologic Oncology ·doi:10.1016/j.ygyno.2017.09.032

OBJECTIVE: Endometrioid (ENOC) and clear cell ovarian carcinoma (CCOC) share a common precursor lesion, endometriosis, hence the designation endometriosis associated ovarian cancers (EAOC). Long interspersed nuclear element 1 (LINE-1 or L1)…